- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06205030
Efficacy of NOSHINtrial in Diabetic Patients (NOSHIN)
January 12, 2024 updated by: Faegheh Bahri, Kerman Medical University
Efficacy of a Traditional Anti-diabetic Herbal Drug on Glycemic, Inflammatory, and Oxidative Stress Parameters in Patients With Type 2 Diabetes
The goal of this [Efficacy of a traditional anti-diabetic herbal drug with on glycemic, inflammatory, and oxidative stress parameters] is [investigate the level of HOMA-estimated insulin resistance as the primary outcome before and after 40 days in intervention and placebo groups] in [patients with type 2 diabetes].
The secondary outcomes of this study are the assessment of oxidative stress, inflammation biomarkers, other glycemic indices, hematopoietic status and lipid profile between the two groups before and after the intervention.
also The food frequency questionnaire (FFQ) and the physical activity questionnaire (FAQ) are used to evaluate the effect of potential confounding factors.
This study has the code of ethics IR.KMU.REC.1402.291
from Kerman University of Medical Sciences and this drug has the number 12/14484 from Iran Food and Drug Administration (IFDA).
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
All the volunteers (Diabetic men and women with HbA1c more than 6.5 from the age of 20 to 65 years who usually use their standard medicine) who meet the entry criteria were directed to the laboratory and imaging center so that biochemical tests can be performed on them before taking the drug.
Volunteers are asked to take the received medicine three times a day after food.
It is worth mentioning that the patients will be divided into two groups by a person outside the research team, one group will drink herbal syrup and the other group will receive a placebo.
A placebo with the same appearance as herbal syrup will drink nectar.
On a weekly basis, the researcher will make phone calls with the applicants and, while reminding and recording the amount of herbal syrup consumed by drinking nectar, will also ask about the possible side effects of consuming herbal syrup drinking nectar.
Then, at the end of the six week, the patient was asked to visit the clinic for a final evaluation.
In this stage, the patient is asked about possible side effects, and the last stage of sample collection will be done to review all the tests of the next stage of receiving the drug (biochemical tests).
Return at the end of week 6.
The sample size in this study is 70 people.
Study Type
Interventional
Enrollment (Estimated)
70
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Kerman, Iran, Islamic Republic of
- Kerman University of Medical Sciences
-
Contact:
- Hossein Pourghadamyari, PhD
- Phone Number: +98 913 379 9109
- Email: ghadamyarih91@gmail.com
-
Contact:
- Faegheh Bahri, PhD
- Phone Number: 09361261331
- Email: faegheh.bahri9797@gmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Age between 20 and 65 years
- HbA1c more than 6.5
- Consistency of diet and exercise program
- Body mass index less than 35
- Not receiving insulin
- The patient should take standard medicine except insulin
Exclusion Criteria:
- Performing CABG surgery, occurrence of ASC, heart and brain stroke, pulmonary embolism, deep vein thrombosis or TIA in the last 1 year.
- Taking anti-inflammatory drugs such as aspirin with an anti-inflammatory dose, antioxidant supplements, vitamins and omega-3 capsules (<1 g/day), and immunosuppressive drugs in the last three months.
- Presence of cancer, liver and thyroid diseases.
- pregnancy
- Smoking and alcohol consumption
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: NOSHIN SHAHD drug
All the volunteers directed to the laboratory so that biochemical tests can be performed on them before taking the drug.
Volunteers are asked to take the received NOSHIN SHAHD drug 20 ml three times per day after food.
at the end of the six week.
then, the sample collection will be done to review all the tests of the end stage of receiving the drug.
|
All the volunteers directed to the laboratory so that biochemical tests can be performed on them before taking the drug.
Volunteers are asked to take the received NOSHIN SHAHD drug 20 ml three times per day after food.
at the end of the six week.
then, the sample collection will be done to review all the tests of the end stage of receiving the drug.
Other Names:
|
Placebo Comparator: placebo
The placebo with the same appearance as the herbal syrup will be drinking nectar.
All the volunteers directed to the laboratory so that biochemical tests can be performed on them before taking the drug.
Volunteers are asked to take the received placebo 20 ml three times per day after food.
at the end of the six week.
then, the sample collection will be done to review all the tests of the end stage of receiving the drug.
|
All the volunteers directed to the laboratory so that biochemical tests can be performed on them before taking the drug.
Volunteers are asked to take the received NOSHIN SHAHD drug 20 ml three times per day after food.
at the end of the six week.
then, the sample collection will be done to review all the tests of the end stage of receiving the drug.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HOMA-estimated insulin resistance
Time Frame: 40 days
|
To investigate the effect of the anti-diabetic herbal drug on changes in HOMA-IR in patients with T2DM
|
40 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
plasma MDA
Time Frame: 40 days
|
Investigating the changes in plasma Malondialdehyde level as an oxidative stress factor
|
40 days
|
plasma protein carbonyl
Time Frame: 40 days
|
Investigating the changes in plasma protein carbonyl level as an oxidative stress factor
|
40 days
|
plasma TAC
Time Frame: 40 days
|
Investigating the changes in plasma total antioxidant capacity as an oxidative stress factor
|
40 days
|
plasma SOD enzyme activity
Time Frame: 40 days
|
Investigating the changes in plasma SOD enzyme activity as an oxidative stress factor
|
40 days
|
plasma catalase enzyme activity
Time Frame: 40 days
|
Investigating the changes in plasma catalase enzyme activity as an oxidative stress factor
|
40 days
|
plasma reduced glutathione
Time Frame: 40 days
|
Investigating the changes in plasma reduced glutathione levels as an oxidative stress factor
|
40 days
|
ROS in PBMCs
Time Frame: 40 days
|
Investigating the changes in ROS level in PBMCs as an oxidative stress factor
|
40 days
|
FBS
Time Frame: 40 days
|
Investigating the changes in fasting blood glucose as a glycemic status
|
40 days
|
fasting blood Insulin
Time Frame: 40 days
|
Investigating the changes in fasting blood Insulin as a glycemic status
|
40 days
|
HbA1c
Time Frame: 40 days
|
Investigating the changes in HbA1c level as a glycemic status
|
40 days
|
Inflammatory biomarkers
Time Frame: 40 days
|
Investigating the changes in plasma TNF-α, IL-6, IL-1β, and hs-CRP levels
|
40 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
WBC count
Time Frame: 40 days
|
Investigating the changes in White blood cell counts as hematopoietic status
|
40 days
|
RBC count
Time Frame: 40 days
|
Investigating the changes in Red blood cell counts as a hematopoietic status
|
40 days
|
Hemoglobin
Time Frame: 40 days
|
Investigating the changes in hemoglobin level as a hematopoietic status
|
40 days
|
Hematocrit
Time Frame: 40 days
|
Investigating the changes in hematocrit level as a hematopoietic status
|
40 days
|
blood MCV
Time Frame: 40 days
|
Investigating the changes in amount of MCV level as a hematopoietic status
|
40 days
|
blood MCH
Time Frame: 40 days
|
Investigating the changes in amount of MCH level as a hematopoietic status
|
40 days
|
blood MCHC
Time Frame: 40 days
|
Investigating the changes in amount of MCHC level as a hematopoietic status
|
40 days
|
serum Urea
Time Frame: 40 days
|
Investigating the changes in serum Urea level as a biochemistry factor
|
40 days
|
serum Uric acid
Time Frame: 40 days
|
Investigating the changes in serum Uric acid level as a biochemistry factor
|
40 days
|
serum Creatinine
Time Frame: 40 days
|
Investigating the changes in serum Creatinine level as a biochemistry factor
|
40 days
|
BUN
Time Frame: 40 days
|
Investigating the changes in Blood urea nitrogen level as a biochemistry factor
|
40 days
|
Total protein
Time Frame: 40 days
|
Investigating the changes in total protein level as a biochemistry factor
|
40 days
|
Albumin
Time Frame: 40 days
|
Investigating the changes in Albumin level as a biochemistry factor
|
40 days
|
ALT
Time Frame: 40 days
|
Investigating the changes in Alanine transaminase level as a biochemistry factor
|
40 days
|
AST
Time Frame: 40 days
|
Investigating the changes in Aspartate Aminotransferase level as a biochemistry factor
|
40 days
|
lipid profile
Time Frame: 40 days
|
Investigating the changes in serum triglyceride, LDL cholesterol, HDL cholesterol, and Total cholesterol levels
|
40 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
June 14, 2024
Primary Completion (Estimated)
February 16, 2025
Study Completion (Estimated)
July 16, 2025
Study Registration Dates
First Submitted
December 19, 2023
First Submitted That Met QC Criteria
January 3, 2024
First Posted (Actual)
January 12, 2024
Study Record Updates
Last Update Posted (Estimated)
January 17, 2024
Last Update Submitted That Met QC Criteria
January 12, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 402000209
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
A part of the data such as the information related to the main outcome or the like can be shared.
Access to study documentation after results are published and It will be available for researchers working in academic and scientific institutions, and also people who are working in the industry can apply for them for secondary studies.
The request sent will be reviewed by the members of the center.
If the members agree, they will be notified.
IPD Sharing Time Frame
Access to study documentation after results are published.
IPD Sharing Access Criteria
It will be available for researchers working in academic and scientific institutions, and also people who are working in the industry can apply for them for secondary studies.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Diabetes Foundation, IndiaNational Diabetes Obesity and Cholesterol FoundationRecruitingType 2 Diabetes Mellitus With ComplicationIndia
Clinical Trials on anti-diabetic herbal drug
-
Taichung Veterans General HospitalRecruiting
-
University of NisCompletedDiabetes Type 2Iran, Islamic Republic of
-
Guangzhou University of Traditional Chinese MedicineUnknown
-
University of FloridaUnited States Department of Agriculture (USDA)Recruiting
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | DiabetesJapan
-
New York Medical CollegeIcahn School of Medicine at Mount SinaiCompleted
-
Ronald PaquetteRecruiting
-
University of ChileUnknownDiabetic Foot UlcerChile
-
Xilis, Inc.Active, not recruitingColorectal NeoplasmsUnited States
-
University Hospital, LinkoepingRecruiting